Huntington Bancshares Incorporated · HBAN · FY2026 Q2 · Calendar Q3 2026

Huntington Bancshares Q2 2026: Strong Organic Growth, EPS Miss on Deposit Cost Pressure

Huntington Bancshares delivered strong Q2 2026 organic growth, with 8.6% sequential loan growth and 9.2% sequential deposit growth, alongside the successful completion of the Cadence systems conversion in just 235 days. Fee revenues expanded 10-46% year-over-year across payments, wealth management, and capital markets. However, EPS of $0.33 missed the consensus estimate of $0.36 by 8.0%, driven by rising deposit costs pressuring net interest margin. Revenue of $2.857 billion modestly exceeded the $2.838 billion estimate by 0.7%. Management maintained full guidance, reaffirming 2027 targets of 18-19% ROTCE and $1.90-$1.93 EPS, with share repurchases scaling to $1.1-1.2 billion in 2027. The stock fell 3.5% on an abnormal basis following the report, with continued negative drift of -3.2% in subsequent sessions on 3.2x baseline volume. The bullish score improved from 78 to 82…

Reported Before market openNASDAQFinancial Services $34.14B market cap
100quality score

Company context

Snapshot as of publication

Huntington Bancshares Incorporated, established in Columbus, Ohio, in 1866, operates as the bank holding company for The Huntington National Bank, providing a comprehensive suite of commercial, consumer, and mortgage banking services across the United States. Its operations are organized into four key segments. The Consumer and Business Banking segment offers essential financial products to individuals and small businesses, including checking, savings, money market, and certificate of deposit accounts, along with credit cards, various loans, and investment opportunities. This segment also facilitates mortgages, insurance, interest rate risk protection, foreign exchange, and provides convenient access through ATMs, online, mobile, and telephone banking.…

Earnings scorecard

Reported versus consensus
Reported EPS $0.33 Consensus $0
EPS surprise -8.0% Reported versus consensus
Reported revenue $2.86B Consensus $2.84B
Revenue surprise +0.7% Reported versus consensus

Earnings History

Estimate Beat Miss Match
HBAN EPS earnings history estimate and actual scatter chart 8 reported fiscal quarters and 4 future estimate-only quarters. Q4 '23 estimate $0.26 Q4 '23 actual $0.27, match Q1 '24 estimate $0.25 Q1 '24 actual $0.26, match Q2 '24 estimate $0.28 Q2 '24 actual $0.30, beat Q2 '25 estimate $0.33 Q2 '25 actual $0.38, beat Q3 '25 estimate $0.37 Q3 '25 actual $0.40, beat Q4 '25 estimate $0.33 Q4 '25 actual $0.31, miss Q1 '26 estimate $0.23 Q1 '26 actual $0.25, beat Q2 '26 estimate $0.36 Q2 '26 actual $0.33, miss Q3 '26 estimate $0.39 Q4 '26 estimate $0.43 Q1 '27 estimate $0.44 Q2 '27 estimate $0.47

Analyst Consensus ?

ConsensusHold48 ratings
Bullish2245.8%
Neutral2347.9%
Bearish36.3%

Analyst 52W Price Targets

$16.84Previous close
$14.5Low
$18.47Average
$22High

Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Truist Securities Buy BuyMaintainJul 28, 2026
Evercore ISI Group Outperform OutperformMaintainJul 28, 2026
B of A Securities Neutral BuyDowngradeJul 27, 2026
Stephens & Co. Equal Weight Equal WeightMaintainJul 24, 2026
Morgan Stanley Equal Weight OverweightDowngradeJul 24, 2026
Baird Outperform OutperformMaintainJul 24, 2026
UBS Buy BuyMaintainJul 7, 2026
JP Morgan Overweight OverweightMaintainJul 6, 2026
Jefferies Hold BuyDowngradeJul 6, 2026
DA Davidson Buy BuyMaintainMar 16, 2026
Keefe, Bruyette & Woods Market Perform Market PerformMaintainJan 23, 2026
Barclays Equal Weight Equal WeightMaintainJan 5, 2026
RBC Capital Outperform OutperformMaintainDec 19, 2025
Piper Sandler Underweight UnderweightMaintainDec 10, 2025
TD Cowen Buy BuyMaintainOct 20, 2025
Raymond James Strong Buy Strong BuyMaintainOct 20, 2025
Wolfe Research Outperform Peer PerformUpgradeJul 3, 2025
Citigroup Buy BuyMaintainJul 2, 2025
Goldman Sachs Buy BuyMaintainNov 26, 2024
Argus Research Buy BuyMaintainJul 22, 2024
Wedbush Neutral NeutralMaintainApr 21, 2023
Deutsche Bank Hold HoldMaintainSep 12, 2022
BMO Capital Market Perform Market PerformMaintainJul 24, 2020
Nomura Neutral NeutralMaintainApr 7, 2020
CFRA Hold HoldMaintainApr 6, 2020
Bank of America Neutral BuyDowngradeOct 25, 2019
Macquarie Underperform NeutralDowngradeJul 12, 2019
Argus Hold HoldMaintainMay 31, 2019
Sandler O'Neill Hold BuyDowngradeNov 29, 2018
Hilliard Lyons Buy NeutralUpgradeFeb 9, 2018
Bernstein Outperform Market PerformUpgradeSep 14, 2017
JMP Securities Perform Market PerformMaintainAug 31, 2017
PiperJaffray Overweight NeutralUpgradeAug 11, 2017
FBR Capital Market Perform OutperformDowngradeOct 11, 2016
Sterne Agee CRT Buy NeutralUpgradeApr 6, 2016
Sterne Agee Buy NeutralUpgradeApr 6, 2016
Credit Suisse Neutral NeutralMaintainJan 22, 2016
Guggenheim Buy NeutralUpgradeAug 28, 2015
CLSA Underperform UnderperformMaintainJul 8, 2015
SunTrust Robinson Humphrey Neutral NeutralMaintainJun 29, 2015
Canaccord Genuity Hold BuyDowngradeMay 11, 2015
Keefe Bruyette & Woods Market Perform OutperformDowngradeApr 24, 2015
Miller Tabak Buy HoldUpgradeMar 9, 2015
Portales Partners Sector Perform UnderperformUpgradeJul 21, 2014
ISI Group Neutral NeutralMaintainOct 7, 2013
Compass Point Neutral BuyDowngradeApr 18, 2013
Evercore Partners Overweight Equal WeightUpgradeDec 19, 2012
Bank oferica Buy BuyMaintainMay 9, 2012
Show less

Named analyst price targets

Upside is calculated against the persisted previous close $16.84. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
Truist FinancialAnalyst unavailable$20$17.24 +18.8%Jul 28, 2026
Robert W. BairdDavid George$21$17.4 +24.7%Jul 24, 2026
StephensAnalyst unavailable$19$17.4 +12.8%Jul 24, 2026
JefferiesAnalyst unavailable$18$17.4 +6.9%Jul 23, 2026
UBSAnalyst unavailable$22$18.03 +30.6%Jul 7, 2026
Evercore ISIJohn Pancari$21$17.76 +24.7%Jul 6, 2026
JefferiesAnalyst unavailable$19$17.86 +12.8%Jul 6, 2026
Morgan StanleyAnalyst unavailable$21$17.81 +24.7%Jun 29, 2026
Evercore ISIAnalyst unavailable$20$17.21 +18.8%Jun 12, 2026
Piper SandlerAnalyst unavailable$18$16.62 +6.9%Apr 23, 2026
Robert W. BairdAnalyst unavailable$20$16.12 +18.8%Mar 9, 2026
UBSAnalyst unavailable$21$19.08 +24.7%Feb 4, 2026
National BankManan Gosalia$21$18.39 +24.7%Feb 4, 2026
RBC CapitalAnalyst unavailable$21$17.8 +24.7%Jan 12, 2026
Wolfe ResearchAnalyst unavailable$21$18.1 +24.7%Jan 7, 2026
Goldman SachsRyan Nash$21$17.99 +24.7%Jan 6, 2026
BarclaysAnalyst unavailable$20$17.48 +18.8%Jan 5, 2026
RBC CapitalAnalyst unavailable$20$17.62 +18.8%Dec 19, 2025
Piper SandlerAnalyst unavailable$16$17 -5.0%Dec 10, 2025
Evercore ISIJohn Pancari$18$15.97 +6.9%Oct 21, 2025
Morgan StanleyAnalyst unavailable$23$17.42 +36.6%Sep 29, 2025
Argus ResearchKevin Heal$17$14.46 +1.0%Apr 25, 2025
Truist FinancialBrian Foran$21$16.55 +24.7%Jan 21, 2025
CitigroupKeith Horowitz$18$15.36 +6.9%Oct 21, 2024
Piper SandlerScott Siefers$15$15.43 -10.9%Oct 18, 2024
Morgan StanleyManan Gosalia$18$13.75 +6.9%Aug 5, 2024
Robert W. BairdDavid George$15$15.06 -10.9%Jul 26, 2024
Argus ResearchKevin Heal$16$15.01 -5.0%Jul 22, 2024
RBC CapitalJon Arfstrom$17$14.86 +1.0%Jul 22, 2024
Morgan StanleyManan Gosalia$16$14.8 -5.0%Jul 22, 2024
D.A. DavidsonPeter Winter$17.5$15.01 +3.9%Jul 22, 2024
StephensTerry McEvoy$16$15.01 -5.0%Jul 22, 2024
Piper SandlerScott Siefers$11.5$12.34 -31.7%Jun 14, 2024
Piper SandlerScott Siefers$13.5$12.77 -19.8%Jun 10, 2024
JefferiesKen Usdin$16$13.6 -5.0%Apr 8, 2024
StephensTerry McEvoy$15$13.95 -10.9%Apr 1, 2024
UBSErika Naharian$15$12.72 -10.9%Feb 14, 2024
D.A. DavidsonAnalyst unavailable$15$14 -10.9%Dec 21, 2022
J.P. MorganAnalyst unavailable$14.5$14.54 -13.9%Dec 13, 2022
Morgan StanleyAnalyst unavailable$19$15.46 +12.8%Dec 5, 2022
Raymond JamesAnalyst unavailable$18$14.1 +6.9%Apr 22, 2022
RBC CapitalJon Arfstrom$19$15.03 +12.8%Jan 21, 2022
BarclaysJason Goldberg$17$15.64 +1.0%Jan 3, 2022
StephensTerry McEvoy$17.5$15.55 +3.9%Nov 9, 2021
Goldman SachsRyan Nash$18$14.27 +6.9%Aug 18, 2021
KBWDavid Konrad$15$13.56 -10.9%Jul 6, 2021
Show less

Track every rating change on HBAN the moment it posts. Free to start.

Start free

Market reaction

prior-close to event-session close
Stock move -4.8% Event window
SPY move -1.2% Same window
Abnormal move -3.5% Stock minus SPY
Volume 3.2× Versus trailing sessions
Subsequent drift -3.2% Up to 20 sessions
HBANSPY benchmark

Follow HBAN with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

Bullish score improved from 78 in Q1 to 82 in Q2. The Cadence systems conversion was completed in 235 days, ahead of the June target referenced in Q1, with deposits actually growing during the conversion weekend. Organic growth accelerated with 8.6% sequential loan growth and 9.2% sequential deposit growth. Fee revenue growth remained strong at 10-46% year-over-year. The EPS miss of $0.33 versus $0.36 consensus was a negative shift, driven by deposit cost pressure on net interest margin. The stock reacted negatively with a 3.5% abnormal decline and -3.2% subsequent drift on 3.2x baseline volume. Regulatory focus shifted from Basel III Endgame capital optimization in Q1 to CCAR stress test results in Q2. Share repurchase plans were scaled up from $550 million in 2026 to $1.1-1.2 billion targeted for 2027 under the $3 billion evergreen authorization.

Guidance delta

Guidance was maintained for the second consecutive quarter. Q1 2026 had seen NIM outlook revised down to the high 3.20% range while fee-income growth guidance was raised to 31-33%. Q2 brought no new guidance changes; management reaffirmed 2027 targets of 18-19% ROTCE and $1.90-$1.93 EPS. Share repurchase plans were scaled up from $550 million in 2026 to $1.1-1.2 billion targeted for 2027 under the $3 billion evergreen authorization announced in Q1.

Key takeaways

  • Q2 organic loan growth of 8.6% sequential and deposit growth of 9.2% sequential demonstrate strong core franchise momentum.
  • Cadence systems conversion completed in 235 days, ahead of schedule, with deposits growing during the conversion weekend -- a rare outcome for bank integrations.
  • On track for $365 million in cost synergies by Q4 and over $1 billion in new pipeline revenue from cross-selling to acquired customers.
  • Fee revenues grew 10-46% year-over-year across payments, wealth management, and capital markets, driving a diversified revenue flywheel.
  • EPS of $0.33 missed the $0.36 consensus estimate by 8.0%; revenue of $2.857 billion modestly beat the $2.838 billion estimate by 0.7%.
  • Guidance unchanged; 2027 ROTCE target of 18-19% and EPS of $1.90-$1.93 reaffirmed.

Management priorities

  • Ramp up marketing spend in the Cadence footprint to accelerate digital deposit acquisition.
  • Continue branch expansions in the Carolinas, Colorado, and Chicago.
  • Further integrate and cross-sell to Cadence customers across payments, wealth, and treasury services.
  • Maintain expense-reduction program targeting over 1.5% baseline OPEX reduction.
  • Execute additional share repurchases of $1.1-1.2 billion in 2027.

Related earnings events

Financial Services

Sources

  1. Earnings call transcript and parsed analysis · 2026-07-23T18:04:23.772433+00:00
  2. FN2 earnings calendar · 2026-07-30T01:23:13.872335+00:00
  3. Polygon adjusted daily market bars · 2026-07-30T08:31:59.281007+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T08:31:59.278391+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.